NCT02237495View on ClinicalTrials.gov

Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

April 9, 2014

Primary Completion Date

March 1, 2017

Study Completion Date

March 31, 2018

Conditions
Heart Valve DiseasesCoronary Artery Disease
Interventions
DRUG

dexmedetomidine

dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.

DRUG

placebo

The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.

Trial Locations (1)

710032

Xijing Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT02237495 - Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS) | Biotech Hunter | Biotech Hunter